Referenzen
Produkte Transfektion
Kostenlose Testsamples
Anwendungshinweise:
Im „Transfection Reagent Selection Guide“ können Sie durch Filterfunktionen z.B. für Ihre Kombination aus zu transfizierender Zelle und Nukleinsäure die Liste vorhandener Referenzen durchsuchen. Ebenso können Sie im Feld „Referenzen durchsuchen“ am Anfang der Seite mit passenden Schlagwörtern zu einem Ergebnis gelangen. Eine Referenz zeigt an, dass das gefundene Transfektionsreagenz bereits erfolgreich für die entsprechende Anwendung verwendet wurde. Im Idealfall sind getestete Transfektionsparameter und Transfektionseffizienzen angegeben.
Keine Referenz? > Allgemeine Auswahlhilfe
Wenn Sie keine Referenz gefunden haben, heißt das nicht, dass kein passendes Reagenz zur Verfügung steht, sondern lediglich, dass bisher keine Erfahrungsberichte vorliegen. In diesem Falle kann durch eine Vorauswahl ein erfolgsversprechendes Transfektionsreagenz ausgewählt (Allgemeine Auswahlhilfe) und letztendlich ausgetestet (Kostenlose Testsamples) werden. Wenn Sie einen Erfahrungsbericht für uns schreiben möchten machen wir Ihnen ein Angebot für eine Gegenleistung.
CELL TYPE | DESCRIPTION OF CELL TYPE | CAT.NO. | SPECIES | ORIGIN OF CELLS | COMMON CELL TYPE | GROWTH PROPERTIES | NUCLEIC ACID / DELIVERED MOLECULE | APPLICATION | PRODUCT | REFERENCE TYPE | BIBLIOGRAPHIC DATA | LINK | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
22Rv1 |
Human prostate epithelial cancer cell line | ATCC CRL-2505 | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | M. Ansems et al., The Prostate, 2012, 72: 1708-1717, DOI 10.1002/pros.22522 | |||
6E4 HeLaT |
Human cervix adenocarcinoma cell line (derivative of HeLa) | Human | genital tract | cell line | adherent | plasmid | cotransfection (plasmid/sgRNA) | Metafectene | publication | D. Kim et al., Nat ure Struct ural & Molec ular Biology, 2020, 27: 581–588, doi.org/10.1038/s41594-020-0427-3 | |||
6E4 HeLaT |
Human cervix adenocarcinoma cell line (derivative of HeLa) | Human | genital tract | cell line | adherent | plasmid | CRISPR | Metafectene | publication | D. Kim et al., Nat ure Struct ural & Molec ular Biology, 2020, 27: 581–588, doi.org/10.1038/s41594-020-0427-3 | |||
A-2780 |
Human ovarian carcinoma cell line | Human | genital tract | cell line | adherent | plasmid | stable transfection | Metafectene PRO | publication | C.F.T. Taute, PhD Thesis, 2013, University of the Western Cape | Link | ||
A-2780 |
Human ovarian carcinoma cell line | Human | genital tract | cell line | adherent | plasmid | Metafectene PRO | publication | C. P. Masamha et al., Cancer Res., Aug 2009; 69: 6565 - 6572 | Link | |||
C4-2 |
Human prostate carcinoma cell line (derivative of LNCaP) | Human | genital tract | cell line | adherent | plasmid | stable transfection | Metafectene PRO | publication | R.C. Peery, Dissertation,, 2020, Indiana University | Link | ||
EFO-27 |
Human ovary adenocarcinoma cell line (cisplatin resistant) | Human | genital tract | cell line | adherent | plasmid | K2 Transfection System | application note | ![]() |
||||
EFO-27 |
Human ovary adenocarcinoma cell line (cisplatin resistant) | Human | genital tract | cell line | adherent | plasmid | stable transfection | K2 Transfection System | application note | ![]() |
|||
EFO-27 |
Human ovary adenocarcinoma cell line (cisplatin resistant) | Human | genital tract | cell line | adherent | plasmid | K2 Transfection System | publication | S. Dilruba et al., Cells, 2020, 9: 515, doi:10.3390/cells9020515 | Link | |||
Flp-In T-REx HeLa |
Human cervix adenocarcinoma cell line (derivative of HeLa) | Human | genital tract | cell line | adherent | plasmid | stable transfection | Metafectene PRO | publication | T. M. Nthiga et al., J. Cell Biol., 2021, 220, 6, doi.org/10.1083/jcb.202006128 | Link | ||
Flp-In T-REx HeLa |
Human cervix adenocarcinoma cell line (derivative of HeLa) | Human | genital tract | cell line | adherent | plasmid | CRISPR | Metafectene PRO | publication | T. M. Nthiga et al., J. Cell Biol., 2021, 220, 6, doi.org/10.1083/jcb.202006128 | Link | ||
Flp-In TREx HeLa |
Human cervix adenocarcinoma cell line (derivative of HeLa) | Human | genital tract | cell line | adherent | plasmid | stable transfection | Metafectene PRO | publication | N.E. Taboko, Masters Thesis, 2020, UiT Norges arktiske universitet | Link | ||
Flp-In TREx HeLa |
Human cervix adenocarcinoma cell line (derivative of HeLa) | Human | genital tract | cell line | adherent | plasmid | CRISPR | Metafectene PRO | publication | T. M. Nthiga et al., The EMBO J., 39: e103649, DOI 10.15252/embj.2019103649 | Link | ||
Flp-In TREx HeLa |
Human cervix adenocarcinoma cell line (derivative of HeLa) | Human | genital tract | cell line | adherent | plasmid | stable transfection | Metafectene PRO | publication | T. M. Nthiga et al., The EMBO J., 39: e103649, DOI 10.15252/embj.2019103649 | Link | ||
Gsalpha |
Human prostate cancer cell line that overexpresses the Gs-alpha protein (derivat of PC3) | Human | genital tract | cell line | adherent | plasmid | RNA-Interference | Metafectene | publication | K. A. Iczkowski et al., Mol Biotechnol, Oct 2004; 28(2): 97-103 | |||
Gsalpha |
Human prostate cancer cell line that overexpresses the Gs-alpha protein (derivat of PC3) | Human | genital tract | cell line | adherent | plasmid | RNA-Interference | Metafectene | publication | A. L. Omara-Opyene et al., Lab Invest., 2004 Jul; 84(7):894-907 | |||
Gsalpha-QL |
Human prostate cancer cell line that overexpresses the Gs-alpha protein (derivat of PC3) | Human | genital tract | cell line | adherent | plasmid | RNA-Interference | Metafectene | publication | K. A. Iczkowski et al., Anticancer Res, Jul 2006; 26: 2863 - 2872 | Link | ||
HEC-1A |
Human endometrial carcinoma cell line | ATCC HTB-112 | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | H. Kiaris et al., PNAS, Aug 2003; 100: 9512 - 9517 | Link | ||
HEK293 |
Human embryonic kidney cell line | ATCC CRL-1573 | Human | genital tract | cell line | adherent | plasmid | cotransfection (plasmid/plasmid) | Metafectene PRO | publication | J. Elvenes et al., PLoS ONE, 2011, 6(9): e24659, doi:10.1371/journal.pone.0024659 | Link | |
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | H. Tanaka et al., FEBS Journal, 2016, 283: 662-677; doi:10.1111/febs.13618 | Link | ||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | stable transfection | Metafectene PRO | publication | Y. P. Abudu et al., J. Cell Biol., 2021, 220(8): e202009092, doi: 10.1083/jcb.202009092 | Link | |
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | stable transfection | Metafectene PRO | publication | S. Pankiv et al., J. Cell Biol., Jan 2010; 188: 253 - 269 | Link | |
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene PRO | application note | ![]() |
|||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | S. Cohen et al., Biochim. et Biophysica Acta, 2013, 1833: 1104–1113, doi.org/10.1016/j.bbamcr.2012.12.021 | Link | ||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene EASY | publication | E. Roscioli et al., J. Cell Biol., Feb 2012; 196: 435 - 450 | Link |